POTASSIUM CHLORIDE IN SODIUM CHLORIDE is a brand name for Sodium Chloride, supplied as a solution. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: AND CLINICAL USE ..........................................................................................3 CONTRAINDICATIONS ...............................................................................................................3 WARNINGS AND PRECAUTIONS…
Verbatim from this product's HC label. Tap a section to expand.
Adverse Drug Reaction Overview Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.
If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary. Symptoms may result from an ion excess or deficit, therefore frequent monitoring of electrolyte levels is essential.
Reactions reported with the use of potassium-containing solutions include nausea, vomiting, abdominal pain, and diarrhea. Signs and symptoms of potassium intoxication include paresthesias of the extremities, areflexia, muscular or respiratory paralysis, mental confusion, weakness, hypotension, cardiac arrhythmias, heart block, and cardiac arrest.
Potassium-containing solutions are irritating to tissues, therefore extreme care should be taken to avoid perivascular infiltration.
Post-Marketing Adverse Reactions Other (Class) Reactions IMMUNE SYSTEM DISORDERS:
Hypersensitivity METABOLISM AND NUTRITIONAL DISORDERS: Hyperkalemia, Hyponatremia, Hypernatremia, Acidosis hyperchloremic, Fluid overload CARDIAC DISORDERS: Cardiac arrest as a manifestation of rapid intravenous administration and/or of hyperkalemia.
NERVOUS SYSTEM DISORDERS:
Hyponatremic encephalopathy DRUG INTERACTIONS Drug-Drug Interactions No studies have been conducted by Baxter Healthcare Corporation. Caution is advised in patients treated with lithium. 45% Sodium Chloride Injection, USP and this can result in decreased lithium levels.
45% Sodium Chloride Injection, USP should be used with caution in patients treated concurrently or recently with agents or products that can cause hyperkalemia or increase the risk of hyperkalemia, such as potassium sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants cyclosporine and tacrolimus.
Administration of potassium in patients treated with such agents is associated with an increased risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia. 45% Sodium Chloride Injection, USP to patients treated with drugs leading to an increased vasopressin effect.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Sodium Chloride in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
v. fluids. 4-methylenedioxy-N-methamphetamine, ifosfamide, antipsycotics, opiods. Drugs potentiating vasopressin action such as chlorpropamide, non steroidal anti-inflammatories (NSAIDS), cyclophosphamide. Vasopressin analogues such as desmopressin, oxytocin, vasopressin, terlipressin.
45% Sodium Chloride Injection, USP should be used with particular caution in patients on concomitant medications that may increase the risk of sodium and fluid retention, such as corticosteroids or corticotrophin. 45% Sodium Chloride Injection, USP should be administered with caution in patients treated on concomitant medications that increase the risk of hyponatremia such as diuretics, and certain antiepileptic and psychotropic medications.
DOSAGE AND ADMINISTRATION Recommended Dose and Dosage Adjustment The choice of the specific potassium chloride and sodium chloride formulation, dosage, volume, rate and duration of administration depend on the age, weight and clinical condition of the patient and concomitant therapy.
Administration should be determined by a physician experienced in intravenous fluid therapy monitored by laboratory determination. 45% Sodium Chloride Injection, USP Prescribing Information Page 10 of 14 Frequent laboratory determinations and clinical evaluations are essential to monitor changes in blood glucose, electrolyte concentrations, and fluid and electrolyte balance during prolonged parenteral therapy.
Fluid administration should be based on calculated maintenance of replacement fluid requirements for each patient. 45% sodium chloride solution with 20 mmol of potassium chloride. Administration To avoid potassium intoxication, do not infuse solutions rapidly.
Infusion rates for the administration of potassium-containing solutions generally should not exceed 10 mmol per hour or 120 mmol per day. The maximum rate of infusion should not exceed 20 mmol per hour in the absence of cardiac monitoring.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Do not administer unless solution is clear and seal is intact. Use of an in-line filter is recommended during administration of all parenteral solutions, where possible.
45% Sodium Chloride Injection, USP in VIAFLEX plastic containers should be infused intravenously using sterile equipment. The osmolarity of a final admixed infusion solution must be taken into account when peripheral administration is considered.
Hyperosmolar solutions may cause venous irritation and phlebitis. Thus, clinically significant Hyperosmolar solutions are recommended to be administered through a large central vein, for rapid […]